Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:DRRX NASDAQ:KIN NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.558,748 shs92 shsDRRXDURECT$1.91$1.53$0.48▼$2.64$59.31M0.92699,433 shsN/AKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRUSMerus$66.90-1.7%$64.69$33.19▼$70.65$5.15B1.19597,667 shs634,796 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%-90.00%0.00%-99.80%DRRXDURECT0.00%-1.04%0.00%+190.85%+22.44%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRUSMerus-1.75%-2.41%-0.52%+27.21%+33.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.558,748 shs92 shsDRRXDURECT$1.91$1.53$0.48▼$2.64$59.31M0.92699,433 shsN/AKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRUSMerus$66.90-1.7%$64.69$33.19▼$70.65$5.15B1.19597,667 shs634,796 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%-90.00%0.00%-99.80%DRRXDURECT0.00%-1.04%0.00%+190.85%+22.44%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRUSMerus-1.75%-2.41%-0.52%+27.21%+33.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/AKINKindred Biosciences 0.00N/AN/AN/AMRUSMerus 3.08Buy$88.7532.66% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, CALA, KIN, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$97.00 ➝ $96.007/29/2025DRRXDURECTNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ADRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29MRUSMerus$36.13M140.04N/AN/A$9.46 per share7.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/ADRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%11/12/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AMRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)Latest DRRX, CALA, KIN, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DRRXDURECT-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ADRRXDURECTN/A0.980.95KINKindred Biosciences0.197.027.02MRUSMerusN/A8.398.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ADRRXDURECT28.03%KINKindred Biosciences66.89%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%DRRXDURECT3.20%KINKindred Biosciences13.69%MRUSMerus3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableDRRXDURECT8031.05 million30.06 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableMRUSMerus3775.63 million72.84 millionOptionableDRRX, CALA, KIN, and MRUS HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Sells 117,398 Shares of Merus N.V. $MRUS3 hours ago | marketbeat.comMerus initiated with an Overweight at BarclaysSeptember 16 at 11:57 PM | msn.comMillennium Management LLC Has $24.68 Million Position in Merus N.V. $MRUSSeptember 14 at 3:37 AM | marketbeat.comMerus (NASDAQ:MRUS) Reaches New 12-Month High - Should You Buy?September 13, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stake in Merus N.V. $MRUSSeptember 12, 2025 | marketbeat.comWoodline Partners LP Raises Stock Holdings in Merus N.V. $MRUSSeptember 11, 2025 | marketbeat.comPolar Asset Management Partners Inc. Reduces Stake in Merus N.V. $MRUSSeptember 9, 2025 | marketbeat.comSamlyn Capital LLC Sells 288,750 Shares of Merus N.V. $MRUSSeptember 8, 2025 | marketbeat.comParkman Healthcare Partners LLC Lowers Stock Holdings in Merus N.V. $MRUSSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Purchases Shares of 12,361 Merus N.V. $MRUSSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Lowers Stake in Merus N.V. $MRUSSeptember 8, 2025 | marketbeat.comMerus N.V.’s Promising Phase 3 Study on Head and Neck Cancer TreatmentSeptember 7, 2025 | tipranks.comMerus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for Head and Neck CancerSeptember 7, 2025 | tipranks.comGranahan Investment Management LLC Sells 8,842 Shares of Merus N.V. $MRUSSeptember 7, 2025 | marketbeat.comAnalysts Set Merus N.V. (NASDAQ:MRUS) Target Price at $88.75September 7, 2025 | americanbankingnews.comMerus N.V. $MRUS Stock Position Boosted by Boothbay Fund Management LLCSeptember 6, 2025 | marketbeat.comTrexquant Investment LP Sells 38,351 Shares of Merus N.V. $MRUSSeptember 6, 2025 | marketbeat.comAllostery Investments LP Increases Position in Merus N.V. $MRUSSeptember 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Reduces Stock Holdings in Merus N.V. $MRUSSeptember 5, 2025 | marketbeat.comMerus N.V. (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 5, 2025 | marketbeat.comBicara Therapeutics: Promising, But Only For The PatientSeptember 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Intel's Silent Comeback: 3 Pillars the Market Is OverlookingBy Jeffrey Neal Johnson | September 12, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025DRRX, CALA, KIN, and MRUS Company DescriptionsCalithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.DURECT NASDAQ:DRRX$1.91 0.00 (0.00%) As of 09/11/2025DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Merus NASDAQ:MRUS$66.90 -1.19 (-1.75%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$68.04 +1.13 (+1.70%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
